Generic drug prices are falling — what that means for your supply strategy

The generic market is growing and the price of individual molecules is falling at the same time, and both trends are structural rather than cyclical. Global generic sales are projected to rise from around USD 445 billion in 2026 towards USD 570 billion by the early 2030s, while the price of a given molecule can fall by as much as ninety per cent once four or more suppliers are approved. Volume is going up and unit price is going down at the same time.

Why the erosion is happening now

Three forces are working together. First, a wave of patent expiries between 2026 and 2028 is releasing a large block of branded revenue to generic substitution — molecules including sitagliptin, apixaban, dabigatran and ticagrelor are among those approaching loss of exclusivity, and the first-to-file applicant is generally positioned to capture the majority of originator volume within months rather than years. Second, payers are pressing harder on price: in the United States, negotiated prices for ten high-spend medicines were reduced by between 38% and 79% for 2026 implementation, and European reference pricing continues to constrain what can be charged. Third, expedited approval pathways and a shortened regulatory review have brought more competitors to market faster than before.

The consequence for anyone buying on price alone

When a molecule has four approved suppliers, the buyer is being offered a genuinely competitive market. The risk in that situation is not that you pay too much. The risk is that you pay the lowest price for the least reliable supply, and only discover the difference when a shipment is late or a batch does not meet specification. Price competition in generics tends to be led by the bidder with the lowest cost base, which is frequently also the bidder with the least margin available for quality investment, second manufacturing sites, or holding inventory against a shortage.

What to change in your approach

Three things are worth doing. Treat minimum order quantity and price as a single commercial conversation rather than separate ones — a supplier offering a lower price at a higher order quantity may be offering you a better position in the market, and there is no way to know without asking. Ask what happens to lead time when the market is oversupplied, because the answer reveals whether you are dealing with a producer that schedules production or one that produces to order. And build a second source for every molecule where a shortage would actually disrupt your business, before you need it, because at the moment of shortage the commercial terms available to you are set by the shortage, not by you.

Where the margin is moving

The categories resisting commoditisation are the more complex presentations — sterile injectables, biologics and biosimilars, and modified-release forms — where development cost and manufacturing complexity create barriers that are harder to replicate than a tablet compression line. The financial data reflects this: injectables and biosimilars are the fastest-growing segments, while simple oral solids remain the largest by volume but the most exposed to price. If your portfolio is weighted towards simple solids, it is worth asking where the next layer of your catalogue should sit, because that is a question about the durability of your supply position rather than about any single product.

This article reflects general industry commentary and does not constitute legal, regulatory or investment advice. Figures cited are drawn from published market research and public regulatory reporting; market conditions vary by molecule and by country and change over time. Always confirm current requirements against the authority in your market before acting.